SPPI [NASD]
Spectrum Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.87 Insider Own0.90% Shs Outstand169.74M Perf Week-2.78%
Market Cap127.44M Forward P/E- EPS next Y-0.13 Insider Trans-15.27% Shs Float161.67M Perf Month-21.13%
Income-138.20M PEG- EPS next Q-0.16 Inst Own41.10% Short Float7.91% Perf Quarter-1.91%
Sales- P/S- EPS this Y25.70% Inst Trans-26.86% Short Ratio5.26 Perf Half Y-59.67%
Book/sh0.33 P/B2.15 EPS next Y69.80% ROA-103.60% Target Price5.60 Perf Year-78.16%
Cash/sh0.50 P/C1.43 EPS next 5Y- ROE-190.30% 52W Range0.60 - 4.54 Perf YTD-44.11%
Dividend- P/FCF- EPS past 5Y-1.30% ROI- 52W High-84.37% Beta2.19
Dividend %- Quick Ratio2.40 Sales past 5Y- Gross Margin- 52W Low18.30% ATR0.08
Employees163 Current Ratio2.40 Sales Q/Q- Oper. Margin- RSI (14)34.16 Volatility7.80% 10.09%
OptionableYes Debt/Eq0.00 EPS Q/Q63.00% Profit Margin- Rel Volume0.39 Prev Close0.71
ShortableYes LT Debt/Eq0.00 EarningsMay 12 AMC Payout- Avg Volume2.43M Price0.71
Recom2.00 SMA20-11.52% SMA50-27.98% SMA200-51.27% Volume952,789 Change0.03%
Sep-17-20Initiated JMP Securities Mkt Outperform $12
Dec-26-19Downgrade Guggenheim Buy → Neutral
Dec-26-19Downgrade Cantor Fitzgerald Overweight → Neutral $17 → $4
Nov-27-19Resumed B. Riley FBR Buy $18
Jul-11-19Initiated B. Riley FBR Buy $18
Mar-15-19Resumed Jefferies Buy $21
Nov-12-18Reiterated B. Riley FBR Buy $35 → $29
Dec-18-17Initiated B. Riley FBR, Inc. Buy $26
Oct-24-17Initiated Guggenheim Buy $32
Oct-19-17Reiterated H.C. Wainwright Buy $20 → $29
Oct-04-17Reiterated H.C. Wainwright Buy $14 → $20
Aug-16-17Resumed H.C. Wainwright Buy $14
Feb-10-17Resumed Jefferies Buy
Nov-05-15Reiterated RBC Capital Mkts Outperform $13 → $12
Aug-07-15Reiterated RBC Capital Mkts Outperform $12 → $13
Apr-02-15Initiated FBR Capital Outperform $9
Feb-23-15Downgrade ROTH Capital Buy → Neutral $15 → $7
Jul-15-14Upgrade R. F. Lafferty Sell → Neutral $7.50
Oct-07-13Initiated HC Wainwright Buy $15
May-29-13Initiated Burrill Institutional Research Mkt Outperform $12
May-17-22 07:00AM  
May-14-22 09:18AM  
May-13-22 12:00AM  
May-12-22 04:00PM  
May-11-22 07:00AM  
May-06-22 07:00AM  
May-05-22 07:00AM  
Apr-11-22 07:00AM  
Apr-04-22 07:00AM  
Mar-18-22 02:05PM  
Mar-17-22 04:00PM  
Mar-11-22 07:00AM  
Mar-10-22 07:00AM  
Mar-07-22 07:54AM  
06:00AM  
Feb-28-22 07:00AM  
Feb-11-22 07:00AM  
Feb-01-22 10:00AM  
Jan-26-22 06:44PM  
Jan-20-22 07:00AM  
Jan-05-22 08:00AM  
Jan-04-22 07:00AM  
Dec-22-21 11:00AM  
Dec-15-21 08:07AM  
Dec-10-21 08:35AM  
Dec-06-21 10:00AM  
07:00AM  
Dec-01-21 04:00PM  
Nov-30-21 07:00AM  
Nov-11-21 07:00AM  
Nov-10-21 08:30PM  
04:00PM  
Nov-03-21 07:00AM  
06:02AM  
Nov-01-21 04:14PM  
02:36PM  
02:11PM  
01:47PM  
12:15PM  
11:30AM  
11:06AM  
10:00AM  
09:13AM  
09:11AM  
07:45AM  
Oct-31-21 10:35AM  
Oct-30-21 01:18PM  
Oct-29-21 03:53PM  
02:23PM  
02:00PM  
01:45PM  
12:40PM  
11:00AM  
09:00AM  
07:40AM  
Oct-28-21 05:45PM  
04:15PM  
03:06PM  
01:37PM  
12:30PM  
11:00AM  
08:59AM  
07:30AM  
05:19AM  
Oct-27-21 10:55PM  
10:42PM  
09:00PM  
05:38PM  
04:10PM  
02:49PM  
01:18PM  
12:31PM  
09:00AM  
07:45AM  
05:40AM  
Oct-26-21 09:45PM  
05:24PM  
03:45PM  
03:00PM  
02:00PM  
01:13PM  
12:45PM  
12:15PM  
11:29AM  
10:00AM  
09:08AM  
07:40AM  
05:40AM  
Oct-25-21 11:38PM  
03:55PM  
03:30PM  
02:50PM  
11:45AM  
11:00AM  
09:00AM  
08:07AM  
Oct-24-21 10:20AM  
Oct-23-21 01:14PM  
09:15AM  
Oct-22-21 03:35PM  
Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology and hematology drug products. The company's products under development include Eflapegrastim, a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia; Poziotinib, a novel irreversible tyrosine kinase inhibitor for non-small cell lung cancer tumors with various mutations; and Anti-CD20-IFNa, an antibody-interferon fusion molecule directed against CD20 that is in Phase I development for the treatment of patients with relapsed or refractory non-Hodgkin's lymphoma, including diffuse large B-cell lymphoma. It has co-development, commercialization, and in-license agreements with Hanmi Pharmaceutical Co. Ltd.; a patent and technology license agreement with The University of Texas M.D. Anderson Cancer Center; and in-license agreement with ImmunGene, Inc. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was incorporated in 1987 and is based in Henderson, Nevada.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
LEBEL FRANCOISChief Medical OfficerApr 05Sale1.411,3671,927252,513Apr 05 05:42 PM
LEBEL FRANCOISChief Medical OfficerApr 04Sale1.351,2051,627253,880Apr 05 05:42 PM
McGahan Keith MChief Legal OfficerMar 16Sale0.7116,31811,521244,940Mar 16 06:39 PM
LEBEL FRANCOISChief Medical OfficerMar 16Sale0.7125,10517,724255,085Mar 16 07:11 PM
GUSTAFSON KURT AEVP & Chief Financial OfficerMar 16Sale0.7116,31811,521317,259Mar 16 06:15 PM
Riga Thomas JCEO & PresidentMar 16Sale0.7118,82913,293568,800Mar 16 06:29 PM
Riga Thomas JCEO & PresidentMar 15Sale0.7020,35614,351587,629Mar 16 06:29 PM
GUSTAFSON KURT AEVP & Chief Financial OfficerMar 15Sale0.7020,65314,560333,577Mar 16 06:15 PM
LEBEL FRANCOISChief Medical OfficerMar 15Sale0.7025,13017,717280,190Mar 16 07:11 PM
McGahan Keith MChief Legal OfficerMar 15Sale0.7014,65810,334261,258Mar 16 06:39 PM
GUSTAFSON KURT AEVP & Chief Financial OfficerFeb 24Sale0.6415,95810,213354,230Feb 24 06:43 PM
McGahan Keith MChief Legal OfficerFeb 24Sale0.6415,0319,620275,916Feb 24 07:21 PM
Riga Thomas JCEO & PresidentFeb 24Sale0.6418,44111,802607,985Feb 24 08:42 PM
LEBEL FRANCOISChief Medical OfficerFeb 24Sale0.6414,7089,413305,320Feb 24 09:04 PM
LEBEL FRANCOISChief Medical OfficerFeb 23Sale0.7013,4669,467320,028Feb 24 09:04 PM
Riga Thomas JCEO & PresidentFeb 23Sale0.7019,95314,027626,426Feb 24 08:42 PM
McGahan Keith MChief Legal OfficerFeb 23Sale0.7013,5139,500290,947Feb 24 07:21 PM
GUSTAFSON KURT AEVP & Chief Financial OfficerFeb 23Sale0.7020,21514,211366,188Feb 24 06:43 PM
LEBEL FRANCOISChief Medical OfficerNov 09Sale2.186,00013,080329,166Nov 10 08:32 PM
LEBEL FRANCOISChief Medical OfficerNov 08Sale2.207,36316,221335,166Nov 10 08:32 PM
LEBEL FRANCOISChief Medical OfficerJun 23Sale4.005,00020,000340,046Jun 23 05:11 PM
LEBEL FRANCOISChief Medical OfficerJun 22Sale4.095,82123,785345,046Jun 23 05:11 PM
McGahan Keith MChief Legal OfficerJun 22Sale4.164,50018,720303,699Jun 22 06:20 PM
McGahan Keith MChief Legal OfficerJun 21Sale4.273,73515,934308,199Jun 22 06:20 PM
Fischer Seth H. Z.DirectorJun 18Sale4.2412,00050,88034,777Jun 22 05:18 PM
Vyas DolatraiDirectorJun 18Sale4.249,00038,16086,346Jun 22 05:06 PM
Ashton WilliamDirectorJun 18Sale4.249,00038,16046,943Jun 22 04:51 PM